SLCO1B1*15 haplotype is associated with rifampin-induced liver injury

被引:43
|
作者
Li, Ling-Min [1 ]
Chen, Lei [1 ]
Deng, Guo-Hong [2 ]
Tan, Wen-Ting [2 ]
Dan, Yun-Jie [2 ]
Wang, Rong-Quan [1 ]
Chen, Wen-Sheng [1 ]
机构
[1] Third Mil Med Univ, Southwest Hosp, Inst Digest Dis, Chongqing 400038, Peoples R China
[2] Third Mil Med Univ, Southwest Hosp, Inst Infect Dis, Chongqing 400038, Peoples R China
关键词
organic anion transporting polypeptide 1B1; polymorphism; haplotype; pharmacogenetics; rifampin-induced liver injury; OATP-C; MAJOR DETERMINANT; RIFAMYCIN SV; EXPRESSION; BILIRUBIN; SYSTEMS; SLC21A6; CELLS; IDENTIFICATION; TUBERCULOSIS;
D O I
10.3892/mmr.2012.900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin. In this study, the association between OATP1B1 polymorphisms and rifampin hepatotoxicity was investigated using integrated population genetic analysis and functional studies. A total of 273 unrelated patients treated with rifampin were recruited. The allele frequencies were examined in patients with drug (rifampin)-induced liver injury (DILI) (n=118) and without (non-DILI) (n=155). Functional analyses were conducted to determine whether the inhibition of bile acids by rifampin was associated with OATP1B1 variants. In the present study, 24 single nucleotide polymorphisms (SNPs) in OATP1B1 were detected in a Chinese population, with two of them causing an amino acid change (rs2306283 and rs4149056). The haplotypes constructed by these two SNPs were OATP1B1 *la,*lb,*5 and *15, with their respective frequencies being 23.44, 66.30, 0.73 and 9.52% in a total of 273 individuals. The logistic regression analysis indicated that the *15 haplotype was associated with susceptibility to DILI (p=0.03, OR=2.04, 95% CI 1.05-3.96). The frequency of the *15 haplotype in DILL patients was significantly higher than that in non-DILI patients (p=0.03). In the subgroup analysis, the *15 haplotype was associated with susceptibility to cholestatic/mixed injury (p=0.03, OR=2.31, 95% CI 1.06-5.02). Functional assessment of the OATP1B1 *15 haplotype revealed that the activity of bile acid uptake was markedly reduced compared to the three other haplotypes. In the inhibition study, the inhibition by rifampin in the *15 haplotype was greater compared to that in the other haplotypes. These results suggest that the OATP1B1 *15 haplotype is an important predisposing factor for rifampin-induced liver injury.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [31] GENETIC POLYMORPHISMS IN SLCO1B1 ARE NOT ASSOCIATED WITH ALTERED VOXILAPREVIR EXPOSURE.
    Garrison, K.
    Song, Q.
    Stamm, L.
    Ling, J.
    Mathias, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S34 - S34
  • [32] SLCO1B1 Polymorphisms are Associated with the Susceptibility to Pulmonary Tuberculosis in Chinese Females
    Li, Wei
    Liu, Wei
    Wang, Xiong
    Dou, Rui
    Zhu, Zunmin
    BIOCHEMICAL GENETICS, 2024, 62 (01) : 385 - 394
  • [33] Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
    Niemi, M
    Kivistö, KT
    Hofmann, U
    Schwab, M
    Eichelbaum, M
    Fromm, MF
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 602 - 604
  • [36] SLCO1B1 polymorphisms and lopinavir plasma concentrations
    Kohlrausch, F. B.
    Estrela, R. de Cassia
    Barroso, P. F.
    Suarez-Kurtz, G.
    PHARMACOGENOMICS, 2010, 11 (07) : 917 - 918
  • [37] GLOBAL ANALYSIS OF GENETIC VARIATION IN SLCO1B1
    Pasanen, Marja K.
    Neuvonen, Pertti J.
    Niemi, Mikko
    DRUG METABOLISM REVIEWS, 2008, 40 : 136 - 137
  • [38] SLCO1B1 Polymorphism and Oral Antidiabetic Drugs
    Kalliokoski, Annikka
    Neuvonen, Pertti J.
    Niemi, Mikko
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 107 (04) : 775 - 781
  • [39] PharmGKB very important pharmacogene: SLCO1B1
    Oshiro, Connie
    Mangravite, Lara
    Klein, Teri
    Altman, Russ
    PHARMACOGENETICS AND GENOMICS, 2010, 20 (03): : 211 - 216
  • [40] SLCO1B1 variants and statin-induced myopathy -: A genomewide study
    Link, E.
    Parish, S.
    Armitage, J.
    Bowman, L.
    Heath, S.
    Matsuda, F.
    Gut, I.
    Lathrop, M.
    Collins, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (08): : 789 - 799